274 related articles for article (PubMed ID: 35280868)
1. Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring
Han Q; He X; Cui L; Qiu Y; Li Y; Chen H; Zhang H
Front Med (Lausanne); 2022; 9():826705. PubMed ID: 35280868
[TBL] [Abstract][Full Text] [Related]
2. A malignant inflammatory myofibroblastic tumor of the hypopharynx harboring the 3a/b variants of the
Muscarella LA; Rossi G; Trombetta D; La Torre A; Di Candia L; Mengoli MC; Sparaneo A; Fazio VM; Graziano P
Oncol Lett; 2017 Feb; 13(2):593-598. PubMed ID: 28356934
[TBL] [Abstract][Full Text] [Related]
3. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
[TBL] [Abstract][Full Text] [Related]
4. A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.
Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I
Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097
[TBL] [Abstract][Full Text] [Related]
5. Primary inflammatory myofibroblastic tumour of the liver: a clinicopathological and genetic study including a subset with ETV6::NTRK3 fusion.
Han Q; Zhang Z; He X; Chen M; Pang X; Chen C; Du T; Zhang H
Histopathology; 2023 May; 82(6):925-936. PubMed ID: 36748182
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.
Coffin CM; Hornick JL; Fletcher CD
Am J Surg Pathol; 2007 Apr; 31(4):509-20. PubMed ID: 17414097
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory myofibroblastic tumor of the urinary bladder with FN1‑ALK gene fusion: A case report.
Son SM; Woo CG; Lee OJ; Kim YJ; Lee HC
Oncol Lett; 2023 Jun; 25(6):227. PubMed ID: 37153035
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
[TBL] [Abstract][Full Text] [Related]
9. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
10. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
[TBL] [Abstract][Full Text] [Related]
11. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
12. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
13. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.
Zhang L; Luan L; Shen L; Xue R; Huang J; Su J; Huang Y; Xu Y; Wang X; Shao Y; Ji Y; Xu C; Hou Y
Virchows Arch; 2023 Mar; 482(3):567-580. PubMed ID: 36624188
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory Myofibroblastic Tumor Driven by Novel
Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
[TBL] [Abstract][Full Text] [Related]
15. Metastatic pulmonary carcinoids with
Lei X; Zhu S; Ren D; Ren F; Li T; Zhou N; Li S; Shi T; Zu L; Song Z; Chalubinska-Fendler J; Denis MG; Bernicker EH; Thomas de Montpréville V; Jiang R; Xu S
Transl Lung Cancer Res; 2022 Jun; 11(6):1176-1184. PubMed ID: 35832448
[TBL] [Abstract][Full Text] [Related]
16. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J
Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
[TBL] [Abstract][Full Text] [Related]
18. A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer.
Xu X; Liu D; Wen J; Chen J; Fan M
Transl Lung Cancer Res; 2020 Dec; 9(6):2500-2507. PubMed ID: 33489810
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors.
Cha YJ; Shim HS
Oncotarget; 2017 Oct; 8(52):89465-89474. PubMed ID: 29163763
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory myofibroblastic tumor of the submandibular gland Harboring MSN-ALK gene fusion: A case report and literature review.
Diao L; Li W; Jiang Q; Huang H; Zhou E; Peng B; Chen X; Zeng Z; He C
Heliyon; 2023 Dec; 9(12):e22928. PubMed ID: 38144359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]